Delving into the Latest Updates on Zhejiang Puli Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Digestive System Disorders

Contrast agent

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Contrast agent	2
Small molecule drug	1

Top 5 Target	Count

NMDA receptor(Glutamate [NMDA] receptor)	1

主要目的：在中国健康受试者中评价高脂高热量餐后状态单次给药浙江普利药业有限公司生产的米拉贝隆缓释片（受试制剂，50mg）与美国上市米拉贝隆缓释片（参比制剂，Myrbetriq®，50mg）的人体生物等效性次要目的：在中国健康受试者中观察高脂高热量餐后状态单次给药米拉贝隆缓释片受试制剂和参比制剂的安全性

[Translation]

Primary objective: To evaluate the bioequivalence of single-dose mirabegron sustained-release tablets (test preparation, 50 mg) produced by Zhejiang Puli Pharmaceutical Co., Ltd. and mirabegron sustained-release tablets (reference preparation, Myrbetriq®, 50 mg) marketed in the United States in healthy Chinese subjects after a high-fat, high-calorie meal. Secondary objective: To observe the safety of single-dose mirabegron sustained-release tablets test preparation and reference preparation in healthy Chinese subjects after a high-fat, high-calorie meal.

Start Date01 Jul 2024

Sponsor / Collaborator

Zhejiang Puli Pharmaceutical Co., Ltd.

CTR20241019 / CompletedNot Applicable

健康志愿者空腹和餐后条件下，单剂量口服500mg受试制剂克拉霉素缓释片和参比制剂克拉霉素缓释片（Klacid SR®，持证商：Mylan Healthcare B.V.）的随机、开放、三周期、部分重复、交叉生物等效性试验

[Translation] A randomized, open-label, three-period, partially replicated, crossover bioequivalence study of a single oral dose of 500 mg of the test formulation clarithromycin extended-release tablets and the reference formulation clarithromycin extended-release tablets (Klacid SR®, licensee: Mylan Healthcare B.V.) in healthy volunteers under fasting and fed conditions

主要目的：在中国健康受试者中评价浙江普利药业有限公司生产的克拉霉素缓释片（受试制剂，500mg）与欧盟上市克拉霉素缓释片（参比制剂，Klacid SR®，持证商：Mylan Healthcare B.V.，500mg）的人体生物等效性。次要目的：观察克拉霉素缓释片受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of clarithromycin extended-release tablets (test preparation, 500 mg) produced by Zhejiang Puli Pharmaceutical Co., Ltd. and clarithromycin extended-release tablets (reference preparation, Klacid SR®, licensee: Mylan Healthcare B.V., 500 mg) marketed in the EU in healthy Chinese subjects. Secondary objective: To observe the safety of the test preparation and reference preparation of clarithromycin extended-release tablets in healthy Chinese subjects.

Start Date15 Apr 2024

Sponsor / Collaborator

Zhejiang Puli Pharmaceutical Co., Ltd.

CTR20240863 / CompletedNot Applicable

米拉贝隆缓释片在中国健康志愿者中空腹状态下生物等效性试验

[Translation] Bioequivalence study of mirabegron sustained-release tablets in Chinese healthy volunteers under fasting condition

主要目的：在中国健康受试者中评价空腹状态单次给药浙江普利药业有限公司生产的米拉贝隆缓释片（受试制剂，50mg）与美国上市米拉贝隆缓释片（参比制剂，Myrbetriq®，50mg）的人体生物等效性次要目的：在中国健康受试者中观察空腹状态单次给药米拉贝隆缓释片受试制剂和参比制剂的安全性

[Translation]

Primary objective: To evaluate the bioequivalence of single-dose mirabegron sustained-release tablets (test preparation, 50 mg) produced by Zhejiang Puli Pharmaceutical Co., Ltd. and mirabegron sustained-release tablets (reference preparation, Myrbetriq®, 50 mg) marketed in the United States in healthy Chinese subjects under fasting conditions Secondary objective: To observe the safety of single-dose mirabegron sustained-release tablets test preparation and reference preparation in healthy Chinese subjects under fasting conditions

Start Date09 Apr 2024

Sponsor / Collaborator

Zhejiang Puli Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Puli Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Puli Pharmaceutical Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Zhejiang Puli Pharmaceutical Co., Ltd.

01 Jul 2013·Journal of Coordination Chemistry

Synthesis, characterization, and nonlinear optical responses of nickel(II) complexes with phenanthroline-based ligands

Author: Liu, Li-Fen ; Zhou, Mao ; Hong, Yu-Qian ; Cai, Zhi-Bin

Three Ni(II) complexes with phenanthroline-based ligands were synthesized and characterized by UV-visible, IR, MS, and elemental anal.Their off-resonance 3rd-order nonlinear optical (NLO)properties were measured using a fs laser and the degenerate 4-wave mixing technique.The 3rd-order NLO susceptibilities χ⁽³⁾ were 3.45-4.37 × 10^-13 esu.The 2nd-order hyperpolarizabilities γ of the mols. were 3.46-4.36 × 10^-31 esu.The response times were 50-74 fs.The influence of the mol. structure on the 3rd-order optical nonlinearity was analyzed.Highly polarizable delocalized π-conjugated electron system is the key factor leading to strong 3rd-order optical nonlinearity.

RSC Advances

Novel A–(π–D–π–A)_1–3 branched fluorophores displaying high two-photon absorption

Author: Cai, Zhi-Bin ; Li, Sheng-Li ; Tian, Yu-Peng ; Shen, Hai-Min ; Zhou, Mao

Novel A–(π–D–π–A)₃ compounds bearing pyridine end groups are apparently effective in achieving large two-photon responses owing to strong charge transfer.

100 Deals associated with Zhejiang Puli Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Puli Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

PL-002	Liver Cancer More	IND Application
Memantine hydrochloride ( NMDA receptor )	-	IND Application
Iron loaded polydopamine amino acid nanomicelle magnetic resonance contrast agent(Ultra theranostics)	Contrast agents More	IND Application